$GNPX
Genprex Inc

2021 Q1 Form 10-Q Financial Statement

#000143774921012395 Filed on May 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.320M $4.090M
YoY Change 5.62% 146.39%
% of Gross Profit
Research & Development $2.169M $1.478M
YoY Change 46.77% 190.9%
% of Gross Profit
Depreciation & Amortization $6.242K $5.353K
YoY Change 16.61% 82.63%
% of Gross Profit
Operating Expenses $2.169M $1.478M
YoY Change 46.77% 190.9%
Operating Profit -$6.492M -$5.576M
YoY Change 16.42% 156.88%
Interest Expense $0.00 $10.00K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.490M -$5.570M
YoY Change 16.52% 157.87%
Income Tax
% Of Pretax Income
Net Earnings -$6.490M -$5.566M
YoY Change 16.59% 157.83%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$142.5K -$199.3K
COMMON SHARES
Basic Shares Outstanding 45.55M 32.85M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.07M $23.08M
YoY Change 103.94% 232.09%
Cash & Equivalents $47.07M $23.08M
Short-Term Investments
Other Short-Term Assets $200.0K $70.00K
YoY Change 185.71% -30.0%
Inventory $3.110M $880.0K
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $50.38M $24.03M
YoY Change 109.63% 240.88%
LONG-TERM ASSETS
Property, Plant & Equipment $37.30K $50.71K
YoY Change -26.45% 69.04%
Goodwill
YoY Change
Intangibles $610.7K $535.9K
YoY Change 13.95% 37.89%
Long-Term Investments
YoY Change
Other Assets $621.4K $557.7K
YoY Change 11.43% 37.76%
Total Long-Term Assets $658.7K $608.4K
YoY Change 8.28% 42.68%
TOTAL ASSETS
Total Short-Term Assets $50.38M $24.03M
Total Long-Term Assets $658.7K $608.4K
Total Assets $51.04M $24.64M
YoY Change 107.13% 229.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $340.0K $640.0K
YoY Change -46.88% 204.76%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $613.6K $697.2K
YoY Change -11.99% 201.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $613.6K $697.2K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $610.0K $700.0K
YoY Change -12.86% 204.35%
SHAREHOLDERS EQUITY
Retained Earnings -$64.91M -$46.05M
YoY Change 40.97% 43.97%
Common Stock $47.32K $32.85K
YoY Change 44.03% 111.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.42M $23.94M
YoY Change
Total Liabilities & Shareholders Equity $51.04M $24.64M
YoY Change 107.13% 229.57%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.490M -$5.566M
YoY Change 16.59% 157.83%
Depreciation, Depletion And Amortization $6.242K $5.353K
YoY Change 16.61% 82.63%
Cash From Operating Activities -$5.465M -$4.518M
YoY Change 20.98% 175.16%
INVESTING ACTIVITIES
Capital Expenditures $91.70K $11.41K
YoY Change 703.55% 177.6%
Acquisitions
YoY Change
Other Investing Activities -$10.00K -$80.00K
YoY Change -87.5%
Cash From Investing Activities -$110.0K -$137.0K
YoY Change -19.69% 927.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.32M $25.73M
YoY Change -1.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $25.32M 25.73M
YoY Change -1.58%
NET CHANGE
Cash From Operating Activities -$5.465M -4.518M
Cash From Investing Activities -$110.0K -137.0K
Cash From Financing Activities $25.32M 25.73M
Net Change In Cash $19.75M 21.08M
YoY Change -6.3% -1373.45%
FREE CASH FLOW
Cash From Operating Activities -$5.465M -$4.518M
Capital Expenditures $91.70K $11.41K
Free Cash Flow -$5.557M -$4.529M
YoY Change 22.7% 175.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
44528
CY2021Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0.50
CY2021Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
CY2021Q1 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1929747
CY2021Q1 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.64
CY2020 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5826781
CY2021Q1 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2020 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.47
CY2021Q1 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2020 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.41
CY2021Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
7.22
CY2020 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
550000
CY2021Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
25000
CY2021Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
25000
CY2021Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
7.22
CY2020Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25731640
CY2021Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25324330
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1
CY2018Q2 gnpx Operating Lease Rent Expense Per Month
OperatingLeaseRentExpensePerMonth
462
CY2021Q1 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
9258
CY2020Q1 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
80857
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2021Q1 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3107900
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000
CY2020 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
199630
CY2020 gnpx Stock Issued During Period Shares Warrants Issued
StockIssuedDuringPeriodSharesWarrantsIssued
5511599
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
338968
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
192968
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115287472
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89295601
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752444
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651088
CY2021Q1 us-gaap Assets
Assets
51036471
CY2020Q4 us-gaap Assets
Assets
31367214
CY2021Q1 us-gaap Assets Current
AssetsCurrent
50377734
CY2020Q4 us-gaap Assets Current
AssetsCurrent
30715407
CY2021Q1 us-gaap Cash
Cash
47068703
CY2020Q4 us-gaap Cash
Cash
27319685
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27319685
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47068703
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23079591
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19749018
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21077099
CY2021Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
47256175
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27091596
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.37
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.40
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
315182
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2154747
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2179747
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47314820
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43117681
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47314820
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43117681
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43118
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
6491695
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
47315
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
5576226
CY2021Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741
CY2021Q1 us-gaap Depreciation
Depreciation
6242
CY2020Q1 us-gaap Depreciation
Depreciation
5353
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4316310
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4092996
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
146493
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
202134
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-655
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12676
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-15592
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-187282
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-102148
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
610696
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37300
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
601625
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1982
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10006
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51036471
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31367214
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
613626
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
450724
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25324330
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25731640
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110030
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137013
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5465282
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4517528
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489713
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566220
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6491695
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5576226
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
621437
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
612366
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
274658
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
257756
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9071
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
44744
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91701
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11412
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
201004
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
384553
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25324330
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25731640
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2537731
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39441
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
127
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
127
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2169143
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1477877
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64911942
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58422229
CY2021Q1 us-gaap Revenues
Revenues
CY2020Q1 us-gaap Revenues
Revenues
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
671738
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
753994
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.91
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
327640
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
373746
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1332500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7974430
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6844069
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.27
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4673149
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.69
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.87
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.43
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y124D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y21D
CY2021Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5000
CY2020 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
51432
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5511599
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
192139
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20650
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
154648
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1550
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2537731
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324330
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1320155
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
23942959
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
50422845
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45546106
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27952742

Files In Submission

Name View Source Status
0001437749-21-012395-index-headers.html Edgar Link pending
0001437749-21-012395-index.html Edgar Link pending
0001437749-21-012395.txt Edgar Link pending
0001437749-21-012395-xbrl.zip Edgar Link pending
ex_240206.htm Edgar Link pending
ex_240207.htm Edgar Link pending
ex_240208.htm Edgar Link pending
ex_240209.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20210331.xml Edgar Link completed
gnpx-20210331.xsd Edgar Link pending
gnpx-20210331_cal.xml Edgar Link unprocessable
gnpx-20210331_def.xml Edgar Link unprocessable
gnpx-20210331_lab.xml Edgar Link unprocessable
gnpx-20210331_pre.xml Edgar Link unprocessable
gnpx20210331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending